ATS 2019—Late-onset asthma: fewer severe exacerbations with dupilumab


  • Tara Haelle
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dupilumab reduced severe exacerbations in adults with uncontrolled, moderate-to-severe asthma with onset >40 years old.

Why this matters

  • Previous results established dupilumab efficacy for uncontrolled, moderate-to-severe asthma but did not report data for late-onset asthma with fixed airway obstruction.

Study design

  • Post hoc analysis of randomized controlled trial with patients with uncontrolled, moderate-to-severe, late-onset (age >40 years) asthma with baseline post-bronchodilator FEV1 
  • FEV1
  • FEV1 ≥0.7: 200 mg q2w dupilumab (n=74) or placebo (n=38) and 300 mg q2w dupilumab (n=72) or placebo (n=41).

Key results

  • Dupilumab significantly reduced annualized rate of severe exacerbations:
    • FEV1
    • FEV1 ≥0.7: −55.1% (200 mg) and −50.7% (300 mg) (P<.05 class=""> 
  • Patients with FEV1
  • Pre-bronchodilator FEV1 from baseline to week 12 (200 mg, P=.01; 300 mg, P=.003) and week 52 (200 mg, P=.004).
  • Post-bronchodilator FEV1 to week 12 (300 mg, P=.003) and week 52 (200 mg, P=.01). 
  • No significant FEV1 improvements for patients with FEV1 ≥0.7.
  • Injection-site reactions were most common adverse events.